1
|
Affiliation(s)
- Michael A Goodman
- a Division of Allergy and Immunology , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.,b Division of Experimental Hematology and Cancer Biology and Hematology , Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA
| | - Donya Moradi Manesh
- b Division of Experimental Hematology and Cancer Biology and Hematology , Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA
| | - Punam Malik
- b Division of Experimental Hematology and Cancer Biology and Hematology , Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA
| | - Marc E Rothenberg
- a Division of Allergy and Immunology , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA
| |
Collapse
|
2
|
Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RB. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res 2014; 20:4520-31. [PMID: 25013123 DOI: 10.1158/1078-0432.ccr-14-0259] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
PURPOSE Predictive biomarkers are required to identify patients who may benefit from the use of BH3 mimetics such as ABT-263. This study investigated the efficacy of ABT-263 against a panel of patient-derived pediatric acute lymphoblastic leukemia (ALL) xenografts and utilized cell and molecular approaches to identify biomarkers that predict in vivo ABT-263 sensitivity. EXPERIMENTAL DESIGN The in vivo efficacy of ABT-263 was tested against a panel of 31 patient-derived ALL xenografts composed of MLL-, BCP-, and T-ALL subtypes. Basal gene expression profiles of ALL xenografts were analyzed and confirmed by quantitative RT-PCR, protein expression and BH3 profiling. An in vitro coculture assay with immortalized human mesenchymal cells was utilized to build a predictive model of in vivo ABT-263 sensitivity. RESULTS ABT-263 demonstrated impressive activity against pediatric ALL xenografts, with 19 of 31 achieving objective responses. Among BCL2 family members, in vivo ABT-263 sensitivity correlated best with low MCL1 mRNA expression levels. BH3 profiling revealed that resistance to ABT-263 correlated with mitochondrial priming by NOXA peptide, suggesting a functional role for MCL1 protein. Using an in vitro coculture assay, a predictive model of in vivo ABT-263 sensitivity was built. Testing this model against 11 xenografts predicted in vivo ABT-263 responses with high sensitivity (50%) and specificity (100%). CONCLUSION These results highlight the in vivo efficacy of ABT-263 against a broad range of pediatric ALL subtypes and shows that a combination of in vitro functional assays can be used to predict its in vivo efficacy.
Collapse
Affiliation(s)
- Santi Suryani
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Hernan Carol
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Triona Ni Chonghaile
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Viktoras Frismantas
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - Chintanu Sarmah
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Laura High
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Beat Bornhauser
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - Mark J Cowley
- Peter Wills Bioinformatics Centre, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Barbara Szymanska
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Kathryn Evans
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Ingrid Boehm
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Elise Tonna
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Luke Jones
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | - Donya Moradi Manesh
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia
| | | | - Catherine Billups
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Warren Kaplan
- Peter Wills Bioinformatics Centre, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Anthony Letai
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Jean-Pierre Bourquin
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - Peter J Houghton
- Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, Ohio
| | | | - Richard B Lock
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, Australia.
| |
Collapse
|
3
|
Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2014; 61:245-52. [PMID: 24038993 PMCID: PMC4225045 DOI: 10.1002/pbc.24724] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Accepted: 07/15/2013] [Indexed: 12/20/2022]
Abstract
BACKGROUND Quisinostat (JNJ-26481585) is a second-generation pyrimidyl-hydroxamic acid histone deacetylase (HDAC) inhibitor with high cellular potency towards Class I and II HDACs. Quisinostat was selected for clinical development as it showed prolonged pharmacodynamic effects in vivo and demonstrated improved single agent antitumoral efficacy compared to other analogs. PROCEDURES Quisinostat was tested against the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10 μM and was tested against the PPTP in vivo panels at a dose of 5 mg/kg (solid tumors) or 2.5 mg/kg (ALL models) administered intraperitoneally daily × 21. RESULTS In vitro quisinostat demonstrated potent cytotoxic activity, with T/C% values approaching 0% for all of the cell lines at the highest concentration tested. The median relative IC50 value for the PPTP cell lines was 2.2 nM (range <1-19 nM). quisinostat induced significant differences in EFS distribution compared to control in 21 of 33 (64%) of the evaluable solid tumor xenografts and in 4 of 8 (50%) of the evaluable ALL xenografts. An objective response was observed in 1 of 33 solid tumor xenografts while for the ALL panel, two xenografts achieved complete response (CR) or maintained CR, and a third ALL xenograft achieved stable disease. CONCLUSIONS Quisinostat demonstrated broad activity in vitro, and retarded growth in the majority of solid tumor xenografts studied. The most consistent in vivo activity signals observed were for the glioblastoma xenografts and T-cell ALL xenografts.
Collapse
Affiliation(s)
- Hernan Carol
- Children’s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
| | | | | | | | - Donya Moradi Manesh
- Children’s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
| | | | | | - Min H. Kang
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - John M. Maris
- Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, PA
| | - Amy Wozniak
- St. Jude Children’s Research Hospital, Memphis, TN
| | | | | | | | | | | | - Richard Lock
- Children’s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
| |
Collapse
|
4
|
Moradi Manesh D, Carol H, Evans K, Richmond J, Jamieson S, Wilson WR, Houghton PJ, Smith MA, Lock RB. Abstract 2745: AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-2745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite the success of current therapies for childhood acute lymphoblastic leukemia (ALL), novel treatments are required to treat high-risk or relapsed patients. PR-104 is a pre-prodrug hydrolyzed in vivo to PR-104A, which is then metabolized under hypoxia by one-electron reductases to DNA cross-linking metabolites. PR-104A is also activated under aerobic conditions by aldo-keto reductase 1C3 (AKR1C3). We previously showed profound in vivo efficacy of PR-104 (550 mg/kg IP weekly x 6) against a panel of T- and B-ALL xenografts derived from direct patient explants in immune-deficient mice. However, testing at doses as low as 10% of the MTD (50-200 mg/kg) showed retention of efficacy against a T-ALL but not a B-ALL xenograft. This study aimed to further evaluate PR-104 as a novel treatment for high-risk T-ALL by testing its in vivo efficacy against a large panel of pediatric ALL xenografts both as a single agent and in combination with established drugs. We also aimed to evaluate AKR1C3 as a biomarker of in vivo PR-104 sensitivity in T-ALL. PR-104A was significantly more cytotoxic in vitro against 8 T-ALL compared to 8 B-ALL xenografts (median IC50 value 9-fold higher in B-ALL; P<0.0001), indicating that the difference in sensitivity is a cell-intrinsic phenomenon. Microarray analysis of gene expression, qRT-PCR and immunoblotting showed that AKR1C3 expression was significantly higher in T-ALL compared with B-ALL xenografts (P<0.01). We also observed a strong correlation between AKR1C3 mRNA and protein expression and enzymatic activity (P<0.0001). Moreover, AKR1C3 protein expression significantly correlated with in vitro sensitivity of xenografts to PR104A as assessed by Alamar blue cytotoxicity assay (P=0.0003). The in vivo efficacy of PR-104 was assessed using stringent objective response criteria modeled after the clinical setting, as well as time to event measurements. PR-104 administered as a single agent at a dose that provides pharmacokinetics that are readily achievable in adult leukemia patients (200 mg/kg weekly x 2) was more effective in inducing regression and progression delay of 3/3 chemoresistant T-ALL xenografts compared with an induction-type regimen of vincristine (0.15 mg/kg weekly x 2), dexamethasone (5 mg/kg daily x 5 x 2) and L-asparaginase (1,000 KU/kg daily x 5 x 2) (VXL). However, no therapeutic enhancement was observed in the combination of PR-104 with VXL. These results indicate that PR-104 shows promise as a novel therapy for the treatment of aggressive and chemoresistant T-ALL, and that AKR1C3 is a potential biomarker of in vivo PR-104 efficacy. The optimal combinations of PR-104 that result in therapeutic synergy with established drugs remain to be defined. Our findings have implications for the clinical development of PR-104, since patients with T-ALL may represent a particularly responsive population. This study was supported by NCI NO1CM42216 and Proacta, Inc.
Citation Format: Donya Moradi Manesh, Hernan Carol, Kathryn Evans, Jennifer Richmond, Stephen Jamieson, William R. Wilson, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock. AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2745. doi:10.1158/1538-7445.AM2013-2745
Collapse
Affiliation(s)
- Donya Moradi Manesh
- 1Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
| | - Hernan Carol
- 1Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
| | - Kathryn Evans
- 1Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
| | - Jennifer Richmond
- 1Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
| | - Stephen Jamieson
- 2Auckland Cancer Society Research Centre, The University of Auckland, New Zealand
| | - William R. Wilson
- 2Auckland Cancer Society Research Centre, The University of Auckland, New Zealand
| | | | | | - Richard B. Lock
- 1Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
| |
Collapse
|